Trevi Therapeutics (TRVI) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks (ZYME) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 60.8% versus a gain of 37.6%. Over five years, TRVI leads with a +918.6% price change compared with +2.3% for ZYME. Zymeworks is the larger company by market cap ($1.83 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | ZYME |
|---|---|---|
| Share price | $12.77 | $25.50 |
| Market cap | $1.82B | $1.83B |
| 1-day change | -2.82% | -3.90% |
| YTD return | +4.95% | +0.76% |
| 1-year return | +37.59% | +60.79% |
| 5-year return | +918.60% | +2.27% |
| Forward P/E | — | 29.24 |
| EPS (TTM) | $-0.35 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.22 | $31.34 |
| 52-week low | $9.28 | $16.00 |
| Distance from 52-week high | -36.84% | -18.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +120.67% | +61.64% |
| Average volume | 1.95M | 687.87K |
| Shares outstanding | 142.48M | 71.20M |
| Employees | 34 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed TRVI by 23.2 percentage points over the past year.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
TRVI vs ZYME FAQ
Which is bigger, Trevi Therapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.83B compared with $1.82B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, TRVI or ZYME?
ZYME returned +60.79% over the past 12 months, compared with +37.59% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.